CORIELL INSTITUTE FOR MEDICAL RESEARCH INC

As filed

Subsection

03

NTEE code

U500

Classification

8000

Street

403 HADDON AVE

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

• THE CORIELL INSTITUTE FOR MEDICAL RESEARCH IS A WORLD-RENOWNED BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO PREVENTING AND CURING DISEASE. IN PURSUIT OF THIS MISSION, CORIELL SCIENTISTS CONDUCT GROUNDBREAKING RESEARCH IN RARE DISEASES, CANCER, AGING, INFECTIOUS DISEASES, AND PERSONALIZED MEDICINE.A GLOBALLY RECOGNIZED LEADER IN BIOBANKING, CORIELL HAS SERVED AS AN NIH-SUPPORTED CELL REPOSITORY FOR MORE THAN 50 YEARS AND CURRENTLY HOSTS BIOBANKS FOR SEVERAL NATIONAL INSTITUTES OF HEALTH (NIH) INSTITUTES, INCLUDING NIGMS, NINDS, NHGRI, NEI, AND NIA. CORIELL'S RESEARCH AND BIOBANKING PROGRAMS HAVE MADE IT ONE OF NEW JERSEY'S LEADING RECIPIENTS OF NIH FUNDING. IN ADDITION, CORIELL PROVIDES LABORATORY AND BIOBANKING EXPERTISE TO RESEARCHERS AND ORGANIZATIONS WORLDWIDE, SUPPORTING THE PROCESSING, STORAGE, AND DISTRIBUTION OF CRITICAL BIOLOGICAL SAMPLES.IN 2023, CORIELL PARTNERED WITH COOPER UNIVERSITY HEALTH CARE AND COOPER MEDICAL SCHOOL OF ROWAN UNIVERSITY TO ESTABLISH THE CAMDEN CANCER RESEARCH CENTER (CCRC), THE FIRST BASIC CANCER RESEARCH CENTER IN SOUTHERN NEW JERSEY.BUILDING ON ITS LEGACY OF SCIENTIFIC INNOVATION, CORIELL ANNOUNCED IN 2025 A PARTNERSHIP WITH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY (NJEDA) TO LAUNCH A NEW STATE-DESIGNATED STRATEGIC INNOVATION CENTER (SIC). THE NEW JERSEY CORIELL LABS INNOVATION CENTER WILL BECOME THE LARGEST PUBLIC LIFE SCIENCES INCUBATOR IN THE REGION, SERVING AS A HUB FOR EMERGING BIOTECHNOLOGY COMPANIES AND FOSTERING COLLABORATION AMONG NEW JERSEY'S ACADEMIC, HEALTHCARE, AND RESEARCH INSTITUTIONS.

  Expenses $18,861,446 · Revenue $23,283,009

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2024

  Revenue

  $25,210,396

  Expenses

  $23,095,330

  Contributions

  $1,693,929

  Grants paid

  $0

• 2023

  Revenue

  $32,105,229

  Expenses

  $24,194,566

  Contributions

  $8,141,077

  Grants paid

  $32,900

• 2022

  Revenue

  $23,412,391

  Expenses

  $22,296,737

  Contributions

  $2,510,168

  Grants paid

  $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $23,280,611

  Expenses

  $20,312,651

  Assets (EOY)

  $27,584,123

• 2020 · 990

  Revenue

  $17,260,020

  Expenses

  $18,093,332

  Assets (EOY)

  $28,357,307

• 2019 · 990

  Revenue

  $16,129,416

  Expenses

  $17,923,789

  Assets (EOY)

  $28,551,963

• 2018 · 990

  Revenue

  $16,234,370

  Expenses

  $17,895,622

  Assets (EOY)

  $29,705,452

• 2017 · 990

  Revenue

  $18,101,056

  Expenses

  $18,700,006

  Assets (EOY)

  $29,566,205

• 2016 · 990

  Revenue

  $19,108,119

  Expenses

  $18,514,348

  Assets (EOY)

  $31,848,750

• 2015 · 990

  Revenue

  $17,788,761

  Expenses

  $20,441,642

  Assets (EOY)

  $34,446,594

• 2014 · 990

  Revenue

  $20,420,316

  Expenses

  $21,751,737

  Assets (EOY)

  $39,599,716

• 2013 · 990

  Revenue

  $18,618,590

  Expenses

  $20,342,949

  Assets (EOY)

  $37,878,126

• 2012 · 990

  Revenue

  — not reported

  Expenses

  $20,534,025

  Assets (EOY)

  $38,815,940

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

• COOPER HEALTH SYSTEM A NEW JERSEY NON-PROFIT CORPORATION

  $1,000,000

  2024 · GENERAL SUPPORT

• COOPER HEALTH SYSTEM A NEW JERSEY NON-PROFIT CORPORATION

  $833,333

  2023 · GENERAL SUPPORT

• AMERICAN CANCER SOCIETY INC

  $300,000

  2024 · Extramural Research Grant

• MELANOMA RESEARCH ALLIANCE FOUNDATION

  $50,000

  2023 · PILOT AWARD

• TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUC

  $48,070

  2022 · Research subcontract

• TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUC

  $16,203

  2023 · Research subcontract

• DRAVET SYNDROME FOUNDATION INC

  $12,617

  2024 · This project aims to establish a biobank of five unique lines of commercially-available induced pluripotent stem cells (iPSCs) from patient blood samples. The cellular reprogramming will be conducted by the Coriell Institute for Medical Research and samples will be housed and distributed through an additional partnership with the Orphan Disease Center at The University of Pennsylvania. Cell lines will be available to researchers in academic and for-profit research settings at a low cost, set to cover the long-term maintenance of the biobank effort.

• INTERNATIONAL F O P ASSOCIATION INC

  $8,000

  2022 · RESEARCH

• SHWACHMAN-DIAMOND SYNDROME ALLIANCE INC

  $8,000

  2022 · Medical Research - Biobank Development

Taxable family

From Schedule R Parts I, III and IV: entities that legally are the filer, and taxable partnerships, corporations and trusts it is related to. These record ownership and control, not shared board members or money.

Other IRS files